Integra LifeSciences receives 'buy' rating — 4 notes

Written by Mary Rechtoris | September 25, 2015 | Print  |

Bank of America analysts upgraded Integra LifeSciences stock from a ''neutral'' rating to a 'buy'' rating, according to WKRB.

Here are four notes:


1. The company's shares traded down 0.38 percent on Mon., Sept. 21.


2. Integra LifeSciences has a 12-month low of $42.09 and a 12-month high of $68.46.


3. The stock has a 50-day moving average of $62.13 and a 200-day moving average of $60.04.


4. The market cap is $2.17 billion and P/E ratio is 53.91.

© Copyright ASC COMMUNICATIONS 2018. Interested in LINKING to or REPRINTING this content? View our policies here.

Top 40 Articles from the Past 6 Months